Biocon issues clarification about USFDA inspection
DSIJ Intelligence / 01 Aug 2017
The company has clarified that the USFDA has issued Form 483 observations after an inspection of the plant.
In response to some media queries about the USFDA inspection of its Bengaluru plant, pharmaceutical major Biocon has said that it was a part of the regular periodic audit for a small molecule injectable.
The company has clarified that the USFDA has issued Form 483 observations after an inspection of the plant. Biocon has responded to the regulator with a Corrective and Preventive Action Plan (CAPA) and is on track to implement them in a timely manner, it said.
Biocon was trading at Rs 378.40, down by Rs 6.05 or 1.57% as at 1026 hours on Tuesday, on the BSE. The stock has hit an intraday low of Rs 368.75.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.